48,802
edits
Difference between revisions of "Prostate cancer"
Jump to navigation
Jump to search
→IHC
(→IHC) |
|||
| Line 521: | Line 521: | ||
==IHC== | ==IHC== | ||
===General recommendations=== | |||
ISUP consensus statement:<ref name=pmid25025364>{{cite journal |author=Amin MB, Epstein JI, Ulbright TM, ''et al.'' |title=Best practices recommendations in the application of immunohistochemistry in urologic pathology: report from the international society of urological pathology consensus conference |journal=Am. J. Surg. Pathol. |volume=38 |issue=8 |pages=1017–22 |year=2014 |month=August |pmid=25025364 |doi=10.1097/PAS.0000000000000254 |url=}}</ref> | |||
*Should ''not'' be used if cancer is obvious. | |||
*Should ''not'' be used if it isn't going change the clinical management. | |||
===Benign prostate versus neoplastic prostate=== | ===Benign prostate versus neoplastic prostate=== | ||
*AMACR +ve. | *AMACR +ve. | ||
**May be positive in hindgut [[neuroendocrine tumour]]s.<ref name=pmid>{{Cite journal | last1 = Azumi | first1 = N. | last2 = Traweek | first2 = ST. | last3 = Battifora | first3 = H. | title = Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies. | journal = Am J Surg Pathol | volume = 15 | issue = 8 | pages = 785-90 | month = Aug | year = 1991 | doi = | PMID = 1712549 }}</ref> | **May be positive in hindgut [[neuroendocrine tumour]]s.<ref name=pmid>{{Cite journal | last1 = Azumi | first1 = N. | last2 = Traweek | first2 = ST. | last3 = Battifora | first3 = H. | title = Prostatic acid phosphatase in carcinoid tumors. Immunohistochemical and immunoblot studies. | journal = Am J Surg Pathol | volume = 15 | issue = 8 | pages = 785-90 | month = Aug | year = 1991 | doi = | PMID = 1712549 }}</ref> | ||
*p63 -ve. | *p63 -ve. | ||
| Line 537: | Line 538: | ||
***Why '''CAP'''? | ***Why '''CAP'''? | ||
****A. '''CA'''ncer of the '''P'''rostate. | ****A. '''CA'''ncer of the '''P'''rostate. | ||
Other IHC stains: | |||
*AR +ve -- in prostate confined cancer. | |||
**Usu. -ve in LN +ve disease.<ref name=pmid20878946>{{Cite journal | last1 = Fleischmann | first1 = A. | last2 = Rocha | first2 = C. | last3 = Schobinger | first3 = S. | last4 = Seiler | first4 = R. | last5 = Wiese | first5 = B. | last6 = Thalmann | first6 = GN. | title = Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. | journal = Prostate | volume = 71 | issue = 5 | pages = 453-60 | month = Apr | year = 2011 | doi = 10.1002/pros.21259 | PMID = 20878946 }}</ref> | |||
*PSA +ve. | |||
*PSAP +ve. | |||
====Prostate carcinoma versus urothelial carcinoma==== | ====Prostate carcinoma versus urothelial carcinoma==== | ||